Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Tata Mot 107.65 4.14
Tata Stl 333.35 2.83
Tata Pow 53.45 4.60
State Ba 268.40 3.24
Icici Ba 399.15 3.17
Clear All Clear Last
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
FII Activity
Mutual Fund Activity
Results Watch
Results Calendar
Results Announced
IPO Watch
Recent News
Broker Research
Research Tutorial
Discussion Forum
Research Reports
Sector Watch
Economy Watch
Dr Reddy`S Laboratories Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
Market Lot: 1Face Value: 5ISIN Demat: INE089A01023
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

Business Profile
Dr. Reddy`s Laboratories was founded by Dr Anji Reddy, a entrepreneur-scientist, in 1984. It started its drug discovery programme in 1993, and within three years it achieved its first breakthrough by outlicensing an anti-diabetes molecule to Novo Nordisk in March 1997.

Dr. Reddy`s is a vertically integrated, global pharmaceutical company with proven research capabilities and presence across the pharmaceutical value chain. It manufactures active pharmaceutical ingredients (APIs) and finished dosage forms and markets them globally, with a focus on United States, Europe, India and Russia. In addition, the drug discovery arm of the company conducts basic research in the areas of diabetes, cardiovascular, inflammation and bacterial infection.

Dr. Reddy`s core businesses of API and branded formulations are well established with an impressive track record. The generics business started operations in 2001.

The company has undertaken expansion into Canada with the Pharmascience Group with a multi-product agreement for the development and marketing of generic products in Canada. It is plannnig the commercialisation of new products for which the products are under trials at various stages of development. It has developed analytical methods for the new products and method validations.

The company acquired betapharm- the fourth-largest generics company in Germany for a total enterprise value of GBP 480 million besides clocking revenues of USD 1 billion in December 2006.

The company disclosed rise of 53.98% in consolidated net profit on y-o-y basis to Rs 4.56 billion, while total income declined 100.00% y-o-y basis to Rs 0.00 million for the quarter ended June 2018.

Recent Developments
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC today announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA).

Dr Reddy's Laboratories announced that audit of the company's Formulations Srikakulum Plant (SEZ) Unit I, Andhra Pradesh by the USFDA, has been completed on January 15, 2019. The company has been issued a Form 483 with 4 observations.

Dr Reddys Laboratories announced the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market as approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy's Laboratories announced that the United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy's Laboratories Inc., concluding that lndivior had not shown that it is likely to succeed on the merits of its infringement case on U.S. Patent No. 9,931,305.

Dr. Reddy's Laboratories today announced that it has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private, an emerging generics pharmaceutical company.

Dr. Reddy's Laboratories announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection

Dr Reddy`S Laboratories announced a sharp rise in consolidated net profit for the quarter ended June 2018. During the quarter, the profit of the company rose 7.72 times to Rs 4,561.00 million from Rs 591.00 million in the same quarter previous year.

Dr. Reddy's Laboratories announced today that it has launched Hervycta (Trastuzumab ), a biosimilar of Roche's Herceptin in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer).

Future Plans
The drug maker today announced the launch of Cresp - the first generic darbepoetin alfa in the world, and the only darbepoetin alfa in India

In Brief

Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited